文献速递技术与安全PETCTMR

FDG PET/CT与FDG PET/MRI在癌症患者中诊断性能的头对头比较:系统综述与Meta分析

Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2024-06-05

该系统综述与Meta分析纳入29项头对头比较研究、共1656例癌症患者,比较FDG PET/CT与FDG PET/MRI的诊断性能。患者水平区域淋巴结转移检测中,PET/MRI汇总敏感度88%、特异度92%,PET/CT分别为86%、86%;病灶水平复发和/或转移检测中,PET/MRI汇总敏感度94%、特异度83%,PET/CT分别为91%、81%。作者结论为PET/MRI在一系列癌症和终点上诊断性能与PET/CT相当或更优。

要点

  • 患者水平区域淋巴结转移:PET/MRI敏感度88%、特异度92%,PET/CT敏感度86%、特异度86%。
  • 病灶水平复发和/或转移:PET/MRI敏感度94%、特异度83%,PET/CT敏感度91%、特异度81%。
  • 单项研究中PET/MRI较PET/CT显示更高的分期准确率、原发肿瘤检出敏感度及肝转移检测性能。

核心结论

  • 在一系列癌症和终点上,PET/MRI诊断性能与PET/CT相当或更优。
  • 研究结果有助于识别PET/MRI可能为肿瘤评估提供临床获益的临床场景。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase和Cochrane系统综述数据库,检索时间2015年7月1日至2023年1月25日。
  • 纳入报告FDG PET/CT与FDG PET/MRI头对头诊断性能比较的癌症患者研究,共29项研究、1656例患者。
  • 对数据充足的终点采用双变量模型进行Meta分析,生成汇总敏感度和特异度估计;其余终点记录单项研究报告的性能。
  • 试验注册号:PROSPERO CRD42023433857。

诊断标准与关键数值

  • 患者水平区域淋巴结转移检测(5项研究):PET/MRI汇总敏感度88%(95%CI 74-95%)、特异度92%(95%CI 71-98%);PET/CT汇总敏感度86%(95%CI 70-94%)、特异度86%(95%CI 68-95%)。
  • 病灶水平复发和/或转移检测(5项研究):PET/MRI汇总敏感度94%(95%CI 78-99%)、特异度83%(95%CI 76-88%);PET/CT汇总敏感度91%(95%CI 77-96%)、特异度81%(95%CI 72-88%)。
  • 未纳入Meta分析的单项研究中,乳腺癌分期准确率PET/MRI 98.0% vs PET/CT 74.5%,结直肠癌分期准确率PET/MRI 96.2% vs PET/CT 69.2%。
  • 宫颈癌原发肿瘤检出敏感度PET/MRI 93.2% vs PET/CT 66.2%。
  • 病灶水平肝转移检测:敏感度PET/MRI 91.1-98.0% vs PET/CT 42.3-71.1%,特异度PET/MRI 100.0% vs PET/CT 83.3-98.6%,准确率PET/MRI 96.5-98.2% vs PET/CT 44.7-86.7%。

临床应用与阅片要点

  • 作者结论为PET/MRI在一系列癌症和终点上诊断性能与PET/CT相当或更优。
  • 作者指出研究结果有助于识别PET/MRI可能为肿瘤评估提供临床获益的临床场景。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The available evidence on the use of FDG PET/MRI performed using an integrated system in patients with cancer has grown substantially. OBJECTIVE. The purpose of this study was to perform a systematic review and meta-analysis comparing the diagnostic performance of FDG PET/CT and FDG PET/MRI in patients with cancer. EVIDENCE ACQUISITION. MEDLINE, Embase, and the Cochrane Database of Systematic Reviews were searched for studies reporting a head-to-head comparison of the diagnostic performance of FDG PET/CT and FDG PET/MRI in patients with cancer from July 1, 2015, to January 25, 2023. The two modalities' diagnostic performance was summarized, stratified by performance end point. For end points with sufficient data, a meta-analysis was performed using bivariate modeling to produce summary estimates of pooled sensitivity and specificity. For the remaining end points, reported performance in individual studies was recorded. EVIDENCE SYNTHESIS. The systematic review included 29 studies with a total of 1656 patients. For patient-level detection of regional nodal metastases (five studies), pooled sensitivity and specificity for PET/MRI were 88% (95% CI, 74-95%) and 92% (95% CI, 71-98%), respectively, and for PET/CT were 86% (95% CI, 70-94%) and 86% (95% CI, 68-95%). For lesion-level detection of recurrence and/or metastases (five studies), pooled sensitivity and specificity for PET/MRI were 94% (95% CI, 78-99%) and 83% (95% CI, 76-88%), respectively, and for PET/CT were 91% (95% CI, 77-96%) and 81% (95% CI, 72-88%). In individual studies not included in the meta-analysis, PET/MRI in comparison with PET/CT showed staging accuracy in breast cancer of 98.0% versus 74.5% and in colorectal cancer of 96.2% versus 69.2%; sensitivity for primary tumor detection in cervical cancer of 93.2% versus 66.2%; and sensitivity, specificity, and accuracy for lesion-level liver metastasis detection of 91.1-98.0% versus 42.3-71.1%, 100.0% versus 83.3-98.6%, and 96.5-98.2% versus 44.7-86.7%, respectively. In three studies, management was more commonly impacted by information from PET/MRI (5.2-11.1%) than PET/CT (0.0-2.6%). CONCLUSION. PET/MRI showed comparable or superior diagnostic performance versus PET/CT across a range of cancers and end points. CLINICAL IMPACT. The findings help to identify clinical settings where PET/MRI may provide clinical benefit for oncologic evaluation. TRIAL REGISTRATION. Prospective Register of Systematic Reviews CRD42023433857.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Singnurkar A, Poon R, Metser U, et al. Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2024. PMID: 39016450. doi:10.2214/AJR.24.31519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。